Co-expression of the homologous proteases fibroblast activation protein and dipeptidyl peptidase-IV in the adult human Langerhans islets

详细信息    查看全文

• 作者：Petr Busek (1)
  Petr Hrabal (2)
  Premysl Fric (3)
  Aleksi Sedo (1)
  
  1. Laboratory of Cancer Cell Biology ; Institute of Biochemistry and Experimental Oncology ; First Faculty of Medicine ; Charles University in Prague ; U Nemocnice 5 ; 128 53 ; Prague 2 ; Czech Republic
  2. Department of Pathology ; Military University Hospital Prague ; Prague 6 ; Czech Republic
  3. Department of Medicine ; First Faculty of Medicine ; Charles University in Prague and Military University Hospital Prague ; Prague 6 ; Czech Republic
  
• 关键词：Dipeptidyl peptidase ; Fibroblast activation protein ; Gliptins ; Diabetes ; Pancreas ; Langerhans islets
• 刊名：Histochemistry and Cell Biology
• 出版年：2015
• 出版时间：May 2015
• 年：2015
• 卷：143
• 期：5
• 页码：497-504
• 全文大小：1,215 KB
• 参考文献：1. Aertgeerts, K (2005) Structural and kinetic analysis of the substrate specificity of human fibroblast activation protein alpha. J Biol Chem 280: pp. 19441-19444 CrossRef
  2. Ajami, K (2008) Stromal cell-derived factors 1alpha and 1beta, inflammatory protein-10 and interferon-inducible T cell chemo-attractant are novel substrates of dipeptidyl peptidase 8. FEBS Lett 582: pp. 819-825 CrossRef
  3. Balaziova, E, Busek, P, Stremenova, J, Sromova, L, Krepela, E, Lizcova, L, Sedo, A (2011) Coupled expression of dipeptidyl peptidase-IV and fibroblast activation protein-alpha in transformed astrocytic cells. Mol Cell Biochem 354: pp. 283-289 CrossRef
  4. Bjelke, JR, Christensen, J, Nielsen, PF, Branner, S, Kanstrup, AB, Wagtmann, N, Rasmussen, HB (2006) Dipeptidyl peptidases 8 and 9: specificity and molecular characterization compared with dipeptidyl peptidase IV. Biochem J 396: pp. 391-399 CrossRef
  5. Bosco, D (2010) Unique arrangement of alpha- and beta-cells in human islets of Langerhans. Diabetes 59: pp. 1202-1210 CrossRef
  6. Brissova, M, Fowler, MJ, Nicholson, WE, Chu, A, Hirshberg, B, Harlan, DM, Powers, AC (2005) Assessment of human pancreatic islet architecture and composition by laser scanning confocal microscopy. J Histochem Cytochem 53: pp. 1087-1097 CrossRef
  7. Busek P, Sedo A (2013) Dipeptidyl peptidase-IV and related proteases in brain tumors. In: Lichtor T (ed) Evolution of the molecular biology of brain tumors and the therapeutic implications. InTech. doi:10.5772/53888
  8. Busek, P, Malik, R, Sedo, A (2004) Dipeptidyl peptidase IV activity and/or structure homologues (DASH) and their substrates in cancer. Int J Biochem Cell Biol 36: pp. 408-421 CrossRef
  9. Busek, P (2012) Dipeptidyl peptidase-IV inhibits glioma cell growth independent of its enzymatic activity. Int J Biochem Cell Biol 44: pp. 738-747 CrossRef
  10. Butler, AE, Campbell-Thompson, M, Gurlo, T, Dawson, DW, Atkinson, M, Butler, PC (2013) Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors. Diabetes 62: pp. 2595-2604 CrossRef
  11. Cabrera, O, Berman, DM, Kenyon, NS, Ricordi, C, Berggren, PO, Caicedo, A (2006) The unique cytoarchitecture of human pancreatic islets has implications for islet cell function. Proc Natl Acad Sci USA 103: pp. 2334-2339 CrossRef
  12. Cohen, SJ (2008) Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 37: pp. 154-158 CrossRef
  13. Dinjens, WN, Kate, J, Linden, EP, Wijnen, JT, Khan, PM, Bosman, FT (1989) Distribution of adenosine deaminase complexing protein (ADCP) in human tissues. J Histochem Cytochem 37: pp. 1869-1875 CrossRef
  14. Donath, MY, Burcelin, R (2013) GLP-1 effects on islets: hormonal, neuronal, or paracrine?. Diabetes Care 36: pp. S145-S148 CrossRef
  15. Drucker, DJ (2013) Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls. Diabetes 62: pp. 3316-3323 CrossRef
  16. Ghersi, G, Dong, H, Goldstein, LA, Yeh, Y, Hakkinen, L, Larjava, HS, Chen, WT (2002) Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex. J Biol Chem 277: pp. 29231-29241 CrossRef
  17. Ghersi, G, Zhao, Q, Salamone, M, Yeh, YY, Zucker, S, Chen, WT (2006) The protease complex consisting of dipeptidyl peptidase IV and seprase plays a role in the migration and invasion of human endothelial cells in collagenous matrices. Cancer Res 66: pp. 4652-4661 CrossRef
  18. Goldstein, LA, Ghersi, G, Pineiro-Sanchez, ML, Salamone, M, Yeh, Y, Flessate, D, Chen, WT (1997) Molecular cloning of seprase: a serine integral membrane protease from human melanoma. Biochim Biophys Acta 1361: pp. 11-19 CrossRef
  19. Gorrell MD et al (2014) DPP4 and FAP in glucose and lipid metabolism and liver injury in mice. In: Australian Diabetes Society and Australian Diabetes Educators Association, Melbourne Convention and Exhibition Centre, 27th-29th August 2014, abstract 18
  20. Goscinski, MA (2008) Seprase, dipeptidyl peptidase IV and urokinase-type plasminogen activator expression in dysplasia and invasive squamous cell carcinoma of the esophagus. A study of 229 cases from Anyang Tumor Hospital, Henan Province, China. Oncology 75: pp. 49-59 CrossRef
  21. Grondin, G, Hooper, NM, LeBel, D (1999) Specific localization of membrane dipeptidase and dipeptidyl peptidase IV in secretion granules of two different pancreatic islet cells. J Histochem Cytochem 47: pp. 489-498 CrossRef
  22. Hamson, EJ, Keane, FM, Tholen, S, Schilling, O, Gorrell, MD (2014) Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy. PROTEOMICS Clin Appl 8: pp. 454-463 CrossRef
  23. Hansen, L, Deacon, CF, Orskov, C, Holst, JJ (1999) Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology 140: pp. 5356-5363
  24. Herman, GA (2005) Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78: pp. 675-688 CrossRef
  25. Hinke, SA (2000) Dipeptidyl peptidase IV (DPIV/CD26) degradation of glucagon. Characterization of glucagon degradation products and DPIV-resistant analogs. J Biol Chem 275: pp. 3827-3834 CrossRef
  26. Imai, Y, Patel, HR, Hawkins, EJ, Doliba, NM, Matschinsky, FM, Ahima, RS (2007) Insulin secretion is increased in pancreatic islets of neuropeptide Y-deficient mice. Endocrinology 148: pp. 5716-5723 CrossRef
  27. Inamoto, T (2007) Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors. Clin Cancer Res 13: pp. 4191-4200 CrossRef
  28. Jacob, M, Chang, L, Pure, E (2012) Fibroblast activation protein in remodeling tissues. Curr Mol Med 12: pp. 1220-1243 CrossRef
  29. Kahn, SE, Cooper, ME, Prato, S (2014) Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 383: pp. 1068-1083 CrossRef
  30. Keane, FM, Nadvi, NA, Yao, TW, Gorrell, MD (2011) Neuropeptide Y, B-type natriuretic peptide, substance P and peptide YY are novel substrates of fibroblast activation protein-alpha. FEBS J 278: pp. 1316-1332 CrossRef
  31. Kim, D (2005) (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)- yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48: pp. 141-151 CrossRef
  32. Koh, DS, Cho, JH, Chen, L (2012) Paracrine interactions within islets of Langerhans. J Mol Neurosci 48: pp. 429-440 CrossRef
  33. Lambeir, AM, Durinx, C, Scharpe, S, Meester, I (2003) Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 40: pp. 209-294 CrossRef
  34. Lichnovsky, V, Lojda, Z, Bocek, M (1991) Distribution of the activity of some peptidases in the pancreas of human embryo. Acta Univ Palacki Olomuc Fac Med 131: pp. 137-143
  35. Liu, Z, Stanojevic, V, Avadhani, S, Yano, T, Habener, JF (2011) Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. Diabetologia 54: pp. 2067-2076 CrossRef
  36. Lojda, Z (1981) Proteinases in pathology. Usefulness of histochemical methods. J Histochem Cytochem 29: pp. 481-493 CrossRef
  37. Lund, A, Knop, FK, Vilsboll, T (2014) Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med 25: pp. 407-414 CrossRef
  38. Lyssenko, V (2011) Pleiotropic effects of GIP on islet function involve osteopontin. Diabetes 60: pp. 2424-2433 CrossRef
  39. Marchetti, P (2012) A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. Diabetologia 55: pp. 3262-3272 CrossRef
  40. Mentlein, R (1999) Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85: pp. 9-24 CrossRef
  41. Mentzel, S, Dijkman, HB, Son, JP, Koene, RA, Assmann, KJ (1996) Organ distribution of aminopeptidase A and dipeptidyl peptidase IV in normal mice. J Histochem Cytochem 44: pp. 445-461 CrossRef
  42. Omar, BA, Liehua, L, Yamada, Y, Seino, Y, Marchetti, P, Ahren, B (2014) Dipeptidyl peptidase 4 (DPP-4) is expressed in mouse and human islets and its activity is decreased in human islets from individuals with type 2 diabetes. Diabetologia 57: pp. 1876-1883 CrossRef
  43. Persson, K, Pacini, G, Sundler, F, Ahren, B (2002) Islet function phenotype in gastrin-releasing peptide receptor gene-deficient mice. Endocrinology 143: pp. 3717-3726 CrossRef
  44. Pospisilik, JA (2001) Metabolism of glucagon by dipeptidyl peptidase IV (CD26). Regul Pept 96: pp. 133-141 CrossRef
  45. Poulsen, MD, Hansen, GH, Dabelsteen, E, Hoyer, PE, Noren, O, Sjostrom, H (1993) Dipeptidyl peptidase IV is sorted to the secretory granules in pancreatic islet A-cells. J Histochem Cytochem 41: pp. 81-88 CrossRef
  46. Rodriguez-Diaz, R, Abdulreda, MH, Formoso, AL, Gans, I, Ricordi, C, Berggren, PO, Caicedo, A (2011) Innervation patterns of autonomic axons in the human endocrine pancreas. Cell Metab 14: pp. 45-54 CrossRef
  47. Sam, AH (2012) Selective ablation of peptide YY cells in adult mice reveals their role in beta cell survival. Gastroenterology 143: pp. 459-468 CrossRef
  48. Sedo, A, Malik, R (2001) Dipeptidyl peptidase IV-like molecules: homologous proteins or homologous activities?. Biochim Biophys Acta 1550: pp. 107-116 CrossRef
  49. Vanhoof, G, Goossens, F, Meester, I, Hendriks, D, Scharpe, S (1995) Proline motifs in peptides and their biological processing. FASEB J 9: pp. 736-744
  50. Waget, A (2011) Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152: pp. 3018-3029 CrossRef
  51. Weir, GC, Mojsov, S, Hendrick, GK, Habener, JF (1989) Glucagonlike peptide I (7-37) actions on endocrine pancreas. Diabetes 38: pp. 338-342 CrossRef
  52. Wesley, UV, Albino, AP, Tiwari, S, Houghton, AN (1999) A role for dipeptidyl peptidase IV in suppressing the malignant phenotype of melanocytic cells. J Exp Med 190: pp. 311-322 CrossRef
  53. Wesley, UV, Tiwari, S, Houghton, AN (2004) Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells. Int J Cancer 109: pp. 855-866 CrossRef
  54. Winzell, MS, Ahren, B (2007) Role of VIP and PACAP in islet function. Peptides 28: pp. 1805-1813 CrossRef
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Anatomy
  Medicine/Public Health, general
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-119X

文摘

Fibroblast activation protein (FAP, seprase, EC 3.4.21.B28) and dipeptidyl peptidase-IV (DPP-IV, CD26, EC 3.4.14.5) are homologous serine proteases implicated in the modulation of the bioavailability and thus the function of a number of biologically active peptides. In spite of their generally nonoverlapping expression patterns, DPP-IV and FAP are co-expressed and probably co-regulated in certain cell types suggesting that for some biological processes their functional synergy is essential. By an in situ enzymatic activity assay, we show an abundant DPP-IV-like enzymatic activity sensitive to a highly specific DPP-IV inhibitor sitagliptin and corresponding DPP-IV immunoreactivity in the adult human islets of Langerhans. Moreover, the homologous protease FAP was present in the human endocrine pancreas and was co-expressed with DPP-IV. DPP-IV and FAP were found in the pancreatic alpha cells as determined by the co-localization with glucagon immunoreactivity. In summary, we show abundant enzymatic activity of the canonical DPP-IV (CD26) in Langerhans islets in the natural tissue context and demonstrate for the first time the co-expression of FAP and DPP-IV in pancreatic alpha cells in adult humans. Given their ability to proteolytically modify several biologically active peptides, both proteases have the potential to modulate the paracrine signaling in the human Langerhans islets.